Related references
Note: Only part of the references are listed.Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Fausto Castagnetti et al.
FRONTIERS IN ONCOLOGY (2021)
Connexin 43 and Connexin 26 Involvement in the Ponatinib-Induced Cardiomyopathy: Sex-Related Differences in a Murine Model
Rosalinda Madonna et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports
Junichiro Yuda et al.
JOURNAL OF MEDICAL CASE REPORTS (2021)
An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod
Roger Hesselstrand et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Redox regulation of immunometabolism
Jonathan Muri et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management
Susanne Saussele et al.
ACTA HAEMATOLOGICA (2020)
Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors
Marco Santoro et al.
CHEMOTHERAPY (2020)
Neutrophil-Derived S100A8/A9 Amplify Granulopoiesis After Myocardial Infarction
Gopalkrishna Sreejit et al.
CIRCULATION (2020)
Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib
Grazia Casavecchia et al.
HEART FAILURE REVIEWS (2020)
Reappraising the role of inflammation in heart failure
Luigi Adamo et al.
NATURE REVIEWS CARDIOLOGY (2020)
Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma
Kapil Agarwal et al.
CLINICAL MEDICINE (2020)
Cells of the adult human heart
Monika Litvinukova et al.
NATURE (2020)
Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity
J. G. Coen van Hasselt et al.
NATURE COMMUNICATIONS (2020)
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines
Joachim Alexandre et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Nicholas J. Short et al.
BLOOD (2020)
Emerging roles of neutrophil-borne S100A8/A9 in cardiovascular inflammation
Gopalkrishna Sreejit et al.
PHARMACOLOGICAL RESEARCH (2020)
Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications
Peter Ferdinandy et al.
EUROPEAN HEART JOURNAL (2019)
Cardio-Oncology: Vascular and Metabolic Perspectives A Scientific Statement From the American Heart Association
Umberto Campia et al.
CIRCULATION (2019)
Cardiomyocyte-GSK-3α promotes mPTP opening and heart failure in mice with chronic pressure overload
Firdos Ahmad et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
T-cell recruitment to the heart: friendly guests or unwelcome visitors?
Robert M. Blanton et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2019)
PF-114, a novel selective inhibitor of BCR-ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells
Ekaterina S. Ivanova et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Ponatinib Protects Mice From Lethal Influenza Infection by Suppressing Cytokine Storm
Si Chen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
Valentin Garcia-Gutierrez et al.
FRONTIERS IN ONCOLOGY (2019)
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Christopher A. Eide et al.
CANCER CELL (2019)
Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies
Anand P. Singh et al.
CARDIOVASCULAR RESEARCH (2019)
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
Matteo Molica et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Cardiomyocyte SMAD4-Dependent TGF-β Signaling is Essential to Maintain Adult Heart Homeostasis
Prachi Umbarkar et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Metabolic Reprogramming in Modulating T Cell Reactive Oxygen Species Generation and Antioxidant Capacity
Josephin N. Rashida Gnanaprakasam et al.
FRONTIERS IN IMMUNOLOGY (2018)
Ponatinib: A Review of Efficacy and Safety
Fulvio Massaro et al.
CURRENT CANCER DRUG TARGETS (2018)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour et al.
LANCET HAEMATOLOGY (2018)
Cardioimmunology: the immune system in cardiac homeostasis and disease
Filip K. Swirski et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Immune mechanisms in heart failure
Yingying Zhang et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
CD45 is a more sensitive marker than CD3 to diagnose lymphocytic myocarditis in the endomyocardiurn
Linde Woudstra et al.
HUMAN PATHOLOGY (2017)
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
Hua Jiang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Arun Sharma et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure
Shyam S. Bansal et al.
CIRCULATION-HEART FAILURE (2017)
In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity
Pervinder Sagoo et al.
NATURE MEDICINE (2016)
Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease An Expanded Cardiovascular Continuum
Peter Libby et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
David J. Dorer et al.
LEUKEMIA RESEARCH (2016)
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival A Systematic Review and Meta-analysis
Jonathan Douxfils et al.
JAMA ONCOLOGY (2016)
Cardiac myosin-Th17 responses promote heart failure in human myocarditis
Jennifer M. Myers et al.
JCI INSIGHT (2016)
Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis
R. F. Schelbergen et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury
M. J. Cross et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Inflammatory cytokines as biomarkers in heart failure
Thor Ueland et al.
CLINICA CHIMICA ACTA (2015)
Ponatinib: Accelerated Disapproval
Justin F. Gainor et al.
ONCOLOGIST (2015)
A Multi-parameter In Vitro Screen in Human Stem Cell-Derived Cardiomyocytes Identifies Ponatinib-Induced Structural and Functional Cardiac Toxicity
Dominique R. Talbert et al.
TOXICOLOGICAL SCIENCES (2015)
Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
Sheridan M. Hoy
DRUGS (2014)
The Accelerated Approval of Oncologic Drugs Lessons From Ponatinib
Vinay Prasad et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
How can we cure a heart in flame? A translational view on inflammation in heart failure
Ulrich Hofmann et al.
BASIC RESEARCH IN CARDIOLOGY (2013)
The immunological axis in heart failure: importance of the leukocyte differential
Muthiah Vaduganathan et al.
HEART FAILURE REVIEWS (2013)
Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities
M. Ren et al.
LEUKEMIA (2013)
S100A8 and S100A9: DAMPs at the Crossroads between Innate Immunity, Traditional Risk Factors, and Cardiovascular Disease
Alexandru Schiopu et al.
MEDIATORS OF INFLAMMATION (2013)
S100A8 and S100A9 Induce Cytokine Expression and Regulate the NLRP3 Inflammasome via ROS-Dependent Activation of NF-kappa B
Jean-Christophe Simard et al.
PLOS ONE (2013)
Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus
Anders A. Bengtsson et al.
ARTHRITIS AND RHEUMATISM (2012)
Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis
Florian Leuschner et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
A clinical perspective of IL-1β as the gatekeeper of inflammation
Charles A. Dinarello
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Distinct different expression of Th17 and Th9 cells in coxsackie virus B3-induced mice viral myocarditis
Kong Qing et al.
VIROLOGY JOURNAL (2011)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites
Filip K. Swirski et al.
SCIENCE (2009)
Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis
John S. Tzartos et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Cytokines and myocardial dysfunction: State of the art
Ayman A. El-Menyar
JOURNAL OF CARDIAC FAILURE (2008)
A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage
Lawrence Steinman
NATURE MEDICINE (2007)
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia
D Rea et al.
LEUKEMIA (2006)
Proinflammatory activities of S100: Proteins S10OA8, S10OA9, and S100A8/A9 induce neutrophil chemotaxis and adhesion
C Ryckman et al.
JOURNAL OF IMMUNOLOGY (2003)
Share Paper
